HUP0102696A2 - Növekedési hormon kiválasztását elősegítő anyagok alkalmazása az étvágy serkentésére vagy növelésére szolgáló gyógyszerkészítmények előállítására - Google Patents
Növekedési hormon kiválasztását elősegítő anyagok alkalmazása az étvágy serkentésére vagy növelésére szolgáló gyógyszerkészítmények előállításáraInfo
- Publication number
- HUP0102696A2 HUP0102696A2 HU0102696A HUP0102696A HUP0102696A2 HU P0102696 A2 HUP0102696 A2 HU P0102696A2 HU 0102696 A HU0102696 A HU 0102696A HU P0102696 A HUP0102696 A HU P0102696A HU P0102696 A2 HUP0102696 A2 HU P0102696A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- atom
- formula
- optionally substituted
- growth hormone
- Prior art date
Links
- 230000036528 appetite Effects 0.000 title abstract 2
- 235000019789 appetite Nutrition 0.000 title abstract 2
- 239000003324 growth hormone secretagogue Substances 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000004936 stimulating effect Effects 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 3
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 3
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000004434 sulfur atom Chemical group 0.000 abstract 2
- 102100033367 Appetite-regulating hormone Human genes 0.000 abstract 1
- 101710111255 Appetite-regulating hormone Proteins 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 230000001430 anti-depressive effect Effects 0.000 abstract 1
- 230000003474 anti-emetic effect Effects 0.000 abstract 1
- 230000000561 anti-psychotic effect Effects 0.000 abstract 1
- 239000000935 antidepressant agent Substances 0.000 abstract 1
- 229940005513 antidepressants Drugs 0.000 abstract 1
- 239000002111 antiemetic agent Substances 0.000 abstract 1
- 229910052785 arsenic Inorganic materials 0.000 abstract 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical group [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 abstract 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 1
- 150000001721 carbon Chemical group 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 abstract 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Nutrition Science (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
(I) ltal nos képletű vegyületek, vagy pedig ezek tautomerjei gyógyszatilag elfogadható sói alkalmaz sa "nmag ban vagy egy tov bbihatóanyaggal, péld ul egy n"vekedési hormon szekretagóg anyaggal,antidepressz nssal, antiemetikummal és/vagy antipszichotikummal együttegy kezelt egyed étv gy nak serkentésére vagy fokoz s ra haszn lhatógyógy szati készítmények elő llít s ra, ahol az (I) ltal nos képletbena szubsztituensek főbb jelentései HET jelentése (a), (b), (c), (d)vagy (e) ltal nos képletű heterociklusos csoport; Y2 jelentéseoxigénatom vagy kénatom; A jelentése kétértékű csoport, péld ul 2-4-tagú, adott esetben oxigénatomot, kénatomot vagy nitrogénatomottartalmazó csoport; Q jelentése egy kovalens k"tés vagymetiléncsoport; W jelentése metincsoport vagy nitrogénatom; Xjelentése adott esetben helyettesített metiléncsoport; Y jelentéseadott esetben helyettesített metiléncsoport, oxigénatom vagy NR2 ltalnos képletű csoport; Z jelentése karbonilcsoport, tiokarbonilcsoportvagy szulfonilcsoport; R3 jelentése adott esetben helyettesített ésadott esetben a szénl ncba ékelve heteroatomo(ka)t tartalmazóalkilcsoport, cikloalkilcsoport, cikloalkenilcsoport, fenilcsoportvagy heterociklusos csoport; R4 jelentése hidrogénatom, alkilcsoportvagy cikloalkilcsoport; vagy pedig R4 és R3 együtt, tov bb azzal aszénatommal együtt, amelyhez kapcsolódnak, cikloalkilcsoportot,cikloalkenilcsoportot, vagy mono- vagy biciklusos heterociklusoscsoportot képez; X4 jelentése hidrogénatom vagy alkilcsoport; vagypedig X4 és R4 együtt, tov bb azzal a nitrogénatommal együtt, amelyhezX4 kapcsolódik, valamint azzal a szénatommal együtt, amelyhez R4kapcsolódik, egy gyűrűs csoportot képez; R6 jelentése egy k"tés vagy -Z1-(CH2)a-C(X5X5a)-(CH2)b-, -(CRaRb)a-E-(CRaRb)b- ltal nos képletűcsoport, R7 és R8 jelentése egym stól függetlenül hidrogénatom vagyadott esetben helyettesített alkilcsoport; vagy R7 és R8 együttesjelentése lehet -(CH2)r-L-(CH2)r- ltal nos képletű csoport. Ó
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21497900P | 2000-06-29 | 2000-06-29 |
Publications (3)
Publication Number | Publication Date |
---|---|
HU0102696D0 HU0102696D0 (en) | 2001-08-28 |
HUP0102696A2 true HUP0102696A2 (hu) | 2002-04-29 |
HUP0102696A3 HUP0102696A3 (en) | 2004-11-29 |
Family
ID=22801146
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0102696A HUP0102696A3 (en) | 2000-06-29 | 2001-06-28 | Use of growth hormone secretagogues for the preparation of pharmaceutical compositions stimulating or increasing appetite |
Country Status (10)
Country | Link |
---|---|
US (1) | US20020086865A1 (hu) |
EP (1) | EP1181933A3 (hu) |
JP (1) | JP2002293743A (hu) |
KR (1) | KR20020002271A (hu) |
AU (1) | AU5410801A (hu) |
CA (1) | CA2351902A1 (hu) |
HU (1) | HUP0102696A3 (hu) |
IL (1) | IL143941A0 (hu) |
NZ (1) | NZ512664A (hu) |
ZA (1) | ZA200105259B (hu) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL144468A0 (en) * | 2000-07-27 | 2002-05-23 | Pfizer Prod Inc | Use of growth hormone secretagogues for improvement of functional health status |
US8637503B2 (en) | 2003-05-16 | 2014-01-28 | Board Of Regents, The University Of Texas System | Phenothiazine enantiomers as agents for the prevention of bone loss |
PE20080145A1 (es) * | 2006-03-21 | 2008-02-11 | Janssen Pharmaceutica Nv | Tetrahidro-pirimidoazepinas como moduladores de trpv1 |
CN101855218A (zh) | 2007-09-13 | 2010-10-06 | 康塞特医药品有限公司 | 氘化的儿茶酚和苯并[d][1,3]间二氧杂环戊烯及其衍生物的合成 |
EP2224929B1 (en) | 2007-12-17 | 2016-05-04 | Janssen Pharmaceutica, N.V. | Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of trpv1 |
ES2959427T3 (es) | 2012-09-27 | 2024-02-26 | Elanco Animal Health Incorporated | Composiciones farmacéuticas para el tratamiento de la inapetencia |
NZ733658A (en) | 2015-01-28 | 2018-07-27 | Aratana Therapeutics Inc | Compositions and methods for chronic use of a weight-gaining compound |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2095786A1 (en) * | 1992-05-08 | 1993-11-09 | Franco J. Vaccarino | Method of stimulating appetite |
US5721251A (en) * | 1993-12-10 | 1998-02-24 | Merck & Co., Inc. | Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone |
US5767124A (en) * | 1995-10-27 | 1998-06-16 | Merck & Co., Inc. | Polymorphic forms of a growth hormone secretagogue |
TW432073B (en) * | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
AU2334097A (en) * | 1996-03-21 | 1997-10-10 | Merck & Co., Inc. | 4-spiroindoline piperidines promote release of growth hormone |
AU2722297A (en) * | 1996-04-03 | 1997-10-22 | Merck & Co., Inc. | Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone |
AU3220097A (en) * | 1996-05-22 | 1997-12-09 | Arch Development Corporation | Sleep quality improvement using a growth hormone secretagogue |
AU4342097A (en) * | 1996-09-13 | 1998-04-02 | Merck & Co., Inc. | Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone |
EP1001970B1 (en) * | 1997-06-25 | 2007-03-07 | Pfizer Inc. | Dipeptide derivatives as growth hormone secretagogues |
UA53716C2 (uk) * | 1997-06-25 | 2003-02-17 | Пфайзер Продактс Інк. | Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти) |
US6358951B1 (en) * | 1998-08-21 | 2002-03-19 | Pfizer Inc. | Growth hormone secretagogues |
-
2001
- 2001-06-08 EP EP01305039A patent/EP1181933A3/en not_active Withdrawn
- 2001-06-21 IL IL14394101A patent/IL143941A0/xx unknown
- 2001-06-26 ZA ZA200105259A patent/ZA200105259B/xx unknown
- 2001-06-26 JP JP2001193024A patent/JP2002293743A/ja active Pending
- 2001-06-27 US US09/893,014 patent/US20020086865A1/en not_active Abandoned
- 2001-06-27 CA CA002351902A patent/CA2351902A1/en not_active Abandoned
- 2001-06-28 NZ NZ512664A patent/NZ512664A/xx unknown
- 2001-06-28 AU AU54108/01A patent/AU5410801A/en not_active Abandoned
- 2001-06-28 KR KR1020010037527A patent/KR20020002271A/ko active IP Right Grant
- 2001-06-28 HU HU0102696A patent/HUP0102696A3/hu unknown
Also Published As
Publication number | Publication date |
---|---|
NZ512664A (en) | 2002-11-26 |
AU5410801A (en) | 2002-01-03 |
EP1181933A3 (en) | 2002-04-10 |
ZA200105259B (en) | 2003-01-02 |
HU0102696D0 (en) | 2001-08-28 |
US20020086865A1 (en) | 2002-07-04 |
JP2002293743A (ja) | 2002-10-09 |
EP1181933A2 (en) | 2002-02-27 |
CA2351902A1 (en) | 2001-12-29 |
KR20020002271A (ko) | 2002-01-09 |
IL143941A0 (en) | 2002-04-21 |
HUP0102696A3 (en) | 2004-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0004259A2 (hu) | VLA-4 által mediált leukocita adhéziót gátló szubsztituált fenilalanin-származékok, ezeket tartalmazó gyógyászati készítmények | |
DE69427708D1 (de) | Stabilisierte arzneizusammensetzung enthaltend 10-hydroxy-7-ethylcamptothecin als lakton-verbindung | |
NO169286C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive benzimidazolin-2-okso-1-karboksylsyrederivater | |
HUP0303391A2 (hu) | Alifás, nitrogéntartalmú 5-tagú gyűrűs vegyületek, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
HUP9900028A2 (hu) | Gyógyászatilag hatásos kinazolinszármazékok, előállításuk, alkalmazásuk és azokat tartalmazó gyógyszerkészítmények | |
NO1998003I1 (no) | Topotecan | |
CA2282890A1 (en) | Therapeutic heterocyclic compounds | |
HUP0004529A2 (hu) | VLA-4 által mediált leukocita adhéziót gátló szulfonilezett dipeptid-származékok, ezeket tartalmazó gyógyászati készítmények, valamint alkalmazásuk | |
DK586588D0 (da) | Terapeutiske heterocycliske forbindelser | |
HUP0100579A2 (hu) | Amino-vajsav-származékok és ezeket tartalmazó gyógyszerkészítmények | |
HUP0102696A2 (hu) | Növekedési hormon kiválasztását elősegítő anyagok alkalmazása az étvágy serkentésére vagy növelésére szolgáló gyógyszerkészítmények előállítására | |
HUP0001865A2 (hu) | Amino-pirimidin-származékok, alkalmazásuk, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények | |
CY1843A (en) | Oxadiazolyl alkyl purin derivatives their preparation and their use in pharmaceutical compositions | |
ES8704165A1 (es) | Un procedimiento para la preparacion de derivados de secocantina | |
ATE92036T1 (de) | Kardiovaskulaer aktive verbindungen. | |
HUP0303204A2 (hu) | 1-Metilkarbapenem-származékok és ezeket tartalmazó gyógyszerkészítmények | |
IL97429A0 (en) | Substituted urea compounds,their preparation and pharmaceutical compositions comprising them | |
TR200200485T2 (tr) | Yeni A-500359 türevleri. | |
SE8702697D0 (sv) | Method of treating ischaemic vascular diseases | |
ATE92037T1 (de) | Kardiovaskulaer aktive verbindungen. | |
ES485828A1 (es) | Procedimiento para la preparacion de piridazinas substitui- das |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |